Related Experiment Video

Updated: Jun 8, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Levosimendan in the treatment of cardiogenic shock

Buerkem Buerkem1, H Lemm, K Krohe

  • 1Department of Medicine III, Martin-Luther-University, Halle, Germany. michael.buerke@medizin.uni-halle.de

Minerva Cardioangiologica
|October 13, 2010
PubMed

Insights

Levosimendan offers improved hemodynamic support for cardiogenic shock patients compared to traditional treatments. This drug enhances cardiac output and reduces vascular resistance, potentially minimizing myocardial damage.

Area of Science:

  • Cardiology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Current cardiogenic shock (CS) treatment involves revascularization, mechanical support, and vasoactive drugs.
  • Dobutamine and norepinephrine are primary pharmacologic agents for CS.
  • Levosimendan presents a novel therapeutic option for inotropic support in CS.

Purpose of the Study:

  • To review the evidence on levosimendan's efficacy and mechanism of action in CS.
  • To compare levosimendan's hemodynamic effects with conventional therapies.
  • To explore levosimendan's potential myocardial protective benefits.

Main Methods:

  • Review of current scientific literature on levosimendan in CS.
  • Inclusion of recent clinical trial data.
  • Analysis of hemodynamic parameters and patient outcomes.

Main Results:

  • Levosimendan significantly increases cardiac index and cardiac power index.
  • It reduces systemic and pulmonary resistance more effectively than standard inotropes.
  • Levosimendan demonstrates faster hemodynamic improvement than intraaortic balloon pump (IABP).
  • Potential benefits include reduced reperfusion injury and myocardial stunning.

Conclusions:

  • Levosimendan is a promising alternative for inotropic support in cardiogenic shock.
  • Its favorable hemodynamic profile and potential cardioprotective effects warrant further investigation.
  • Levosimendan may improve outcomes in CS and post-cardiovascular surgery low cardiac output syndrome.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...